Elutia Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
Monitoring Framework
Key Performance Indicators
NXT-41 FDA 510(k) Clearance QuarterlyTarget: FDA Clearance
NXT-41x FDA Clearance QuarterlyTarget: FDA Clearance
GAAP Gross Margin Quarterly5,790.0%Target: 80.0% at scale
Continuing Operations Net Sales Quarterly3.1M
Watch Items
- FDA clearance timeline for the base biologic matrix NXT-41Trigger: Delay past Q4 2026Action: Re-evaluate commercial launch readiness and cash burn projections.
- FDA clearance timeline for the drug-eluting biologic NXT-41xTrigger: Delay past 1H 2027Action: Assess impact on the $1.5 billion U.S. breast cancer surgery market entry strategy.
- Medtronic Supply Agreement LitigationTrigger: Unfavorable ruling on Medtronic's partial motion to dismiss or counterclaimAction: Review legal defense strategy and potential financial liability provisions.
- SimpliDerm Strategic Divestiture ProcessTrigger: Failure to secure a buyer or strategic partner by end of 2026Action: Re-evaluate capital allocation and operational focus on the NXT-41x platform.
Research as of 20 Jun 2026